<DOC>
	<DOCNO>NCT00378508</DOCNO>
	<brief_summary>This randomize placebo control study test whether single 14 course treatment anti-CD3 monoclonal antibody , hOKT3gamma1 ( Ala-Ala ) , Teplizumab prevent loss insulin secretory capacity individual Type 1 diabetes 4 - 12 month duration since diagnosis .</brief_summary>
	<brief_title>Anti-CD3 mAb Treatment Recent Onset Type 1 Diabetes</brief_title>
	<detailed_description>The study design double blind placebo control trial enroll subject age 8 - 30 diagnosis Type 1 diabetes make 4 - 12 month prior enrollment . A single 14 course treatment mAb hOKT3gamma1 ( Ala-Ala ) , Teplizumab give . The primary endpoint C-peptide response mixed meal 12 month . A total 60 subject enrol ( 30 drug treatment 30 placebo group ) 4 study site : Yale University , University California San Francisco , Children 's Hospital Philadelphia , Barbara Davis Diabetes Center .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>age 8 30 , duration diabetes 4 12 month , weight great 27.5 kg , stimulate Cpeptide &gt; = 0.2 pmol/ml asthma , history hepatitis C , hepatitis B , HIV</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>immune therapy</keyword>
	<keyword>autoimmunity</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>